Journal: mAbs

Article Title: Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody

doi: 10.1080/19420862.2018.1486946

Figure Lengend Snippet: ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.

Article Snippet: Human breast cancer cell line BT-474 (HTB-20), MDA-MB-175VII (HTB-25), SK-BR-3(HTB-30) and HCC1419(CRL-2326) are HER2-positive cell lines, which were obtained from the ATCC, and HCC1419 is trastuzumab-resistant human breast cancer cell line.

Techniques: Activity Assay

Journal: Cancers

Article Title: SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma

doi: 10.3390/cancers11081151

Figure Lengend Snippet: SLMP53-2 inhibits the growth of mutp53-Y220C-expressing tumor cells with no genotoxicity, leading to the differential expression of genes involved in cell cycle and death, lipid metabolism, and endoplasmic reticulum (ER) stress. ( A ) Concentration-response curves for SLMP53-2 in human non-tumoral HFF-1 and tumor mutp53-Y220C-expressing HuH-7 and HCC1419 cells, analyzed by sulforhodamine B (SRB) assay after 48 h treatment with 3.12–50 µM SLMP53-2. Data are mean ± SEM ( n = 5); * p < 0.05, extra sum-of-squares F test. ( B ) IC 50 values of SLMP53-2 and APR-246 in HuH-7 and HCC1419 cells were determined by SRB assay after 48 h treatment with 3.12–50 µM SLMP53-2 or APR-246. Data are mean ± SEM ( n = 5); * p < 0.05, two-way ANOVA with Sidak’s multiple comparison test. ( C ) Effect of SLMP53-2 in HuH-7 cell colony formation, analyzed after 14 days incubation with SLMP53-2; a representative experiment is shown. Data are mean ± SEM ( n = 5); values significantly different from DMSO: * p < 0.05, one-way ANOVA with Dunnett’s multiple comparison test. ( D ) Levels of γH2AX in HuH-7 cells treated with SLMP53-2; 50 µM etoposide was used as a positive control (PC). ( E ) Levels of mutp53 phosphorylation at Ser15 in HuH-7 cells treated with 14 µM SLMP53-2. In ( D , E ), immunoblots represent one of three independent experiments; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. ( F ) Top enriched biological pathways grouped by broad categories based on Ingenuity Pathway Analysis (IPA) starting from the dataset of differentially expressed genes (DEGs) from HuH-7 cells treated with 28 µM SLMP53-2. The number of features for each functional annotation is given in parenthesis. The score combines the log10 p -value and predicted pathway activation or repression status of the corresponding pathway/process, respectively for positive and negative score. The different colors correspond to the different functional annotation categories. ( G ) Top scoring upstream regulators inferred from the same gene expression dataset. The score is the log10 p -value of the predicted activation status. ( H ) Gene expression changes of NUPR1 (blue) and ATF4 (yellow) target genes in SLMP53-2-treated HuH-7 cells.

Article Snippet: Human non-small cell lung carcinoma NCI-H1299, breast ductal carcinoma HCC1419, and non-tumorigenic foreskin fibroblast HFF-1 cell lines were purchased from ATCC (Rockville, MD, USA).

Techniques: Expressing, Concentration Assay, Sulforhodamine B Assay, Incubation, Positive Control, Western Blot, Functional Assay, Activation Assay